{"entity":{"id":"nct06982924","kind":"trial","name":"A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.","aka":["LIBRA"],"tldr":"A phase 2 trial of limertinib and bevacizumab in lung cancer, run by Shanghai Chest Hospital, not yet recruiting.","summary":"A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC. is a phase 2, randomised interventional study registered as NCT06982924 by Shanghai Chest Hospital, with a registry enrolment figure of 136 participants, started 2025-06-30 and due to reach its primary completion in 2026-12-30. Interventions recorded: Limertinib+bevacizumab; Limertinib. Conditions listed: EGFR Mutation Positive Advanced Non Small Cell Lung Cancer; PD-L1 Positive. Primary outcome: PFS. Lung eligibility wording from the registry: \"Histologically or cytologically confirmed non - squamous non - small cell lung cancer (NSCLC)\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06982924","url":"https://clinicaltrials.gov/study/NCT06982924"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc"],"sections":[],"technologies":["antiangiogenic","monoclonal-antibody"],"targets":[],"drugs":["limertinib","bevacizumab"],"companies":["innovent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06982924","phase":"2","setting":"A Prospective, Controlled Phase II Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib Monotherapy as First - Line Treatment for Locally Advanced or Recurrent Metastatic Non - Squamous NSCLC With EGFR Mutations and High PD-L1 Expression.","sponsor":"Shanghai Chest Hospital","enrolled":136,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06982924/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"limertinib","kind":"drug","name":"Limertinib","route":"/drugs/limertinib/"}],"company":[{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}